Literature DB >> 26933748

Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic.

Sanchit Bhasin1, Harminder Singh, Laura E Targownik, Eran Israeli, Charles N Bernstein.   

Abstract

BACKGROUND: We aimed to determine the rates and reasons for nonuse of inflammatory bowel disease (IBD)-specific medication in a referral clinic.
METHODS: Consecutive persons with Crohn's disease (CD) (n = 423) and ulcerative colitis (UC) (n = 342) were followed in a single clinic over 2 years. At each patient visit, it was determined whether and what type of IBD-specific medications were used at that visit. If medications were not used, the reason for nonuse was recorded. Disease remission, further stratified by "clinical remission" and "deep remission" (clinical remission plus imaging evidence of remission), was considered a reason for nonuse if the attending physician believed the person was in remission and agreed for them to be off medications.
RESULTS: Nonuse of IBD-specific medication was seen in 121 persons with CD (29%) and 65 persons with UC (18%). In CD, increased age and disease duration were associated with nonuse; disease phenotype did not predict nonuse. In UC, disease duration was associated with nonuse but age was not. In CD, the most common reason for medication nonuse was deep remission (22.5%), followed by clinical remission (21.4%), not having seen a gastroenterologist for a lengthy period (21.4%) and nonadherence (16%). In UC, nonuse was attributed to deep remission (27.7%), followed by nonadherence (26.3%) and clinical remission (23%).
CONCLUSIONS: Approximately a quarter of persons with IBD attending at a tertiary care practice do not use IBD-specific medications with a higher rate in CD than UC. The decision not to use medications was deemed appropriate in approximately one-half of all nonusers.

Entities:  

Mesh:

Year:  2016        PMID: 26933748     DOI: 10.1097/MIB.0000000000000753

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  8 in total

1.  Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2018-03       Impact factor: 10.864

2.  Prevalence and Associated Factors of Sexual Dysfunction in Patients With Inflammatory Bowel Disease.

Authors:  Jinzhi Zhang; Jiao Nie; Min Zou; Qishan Zeng; Yue Feng; Zhenyi Luo; Huatian Gan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-22       Impact factor: 6.055

3.  Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease.

Authors:  James W Varni; Robert J Shulman; Mariella M Self; Shehzad A Saeed; George M Zacur; Ashish S Patel; Samuel Nurko; Deborah A Neigut; James P Franciosi; Miguel Saps; Jolanda M Denham; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl
Journal:  Qual Life Res       Date:  2017-09-08       Impact factor: 4.147

4.  Gelatin versus its two major degradation products, prolyl-hydroxyproline and glycine, as supportive therapy in experimental colitis in mice.

Authors:  Suqin Zhu; Min Huang; Guangxin Feng; Yu Miao; Haohao Wu; Mingyong Zeng; Yangming Martin Lo
Journal:  Food Sci Nutr       Date:  2018-04-16       Impact factor: 2.863

5.  Natural history of children with mild Crohn's disease.

Authors:  Yamini Sharma; Athos Bousvaros; Enju Liu; Julia Bender Stern
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

6.  Gastroenterologist Consultation Is Uncommon but Associated with Improved Care Among IBD Patients Presenting to Emergency Departments in Winnipeg Hospitals.

Authors:  Charles N Bernstein; Elise Crocker; Zoann Nugent; Paramvir Virdi; Harminder Singh; Laura E Targownik
Journal:  J Can Assoc Gastroenterol       Date:  2020-02-17

Review 7.  An Examination of Diet for the Maintenance of Remission in Inflammatory Bowel Disease.

Authors:  Natasha Haskey; Deanna L Gibson
Journal:  Nutrients       Date:  2017-03-10       Impact factor: 5.717

8.  Computational drug repositioning of atorvastatin for ulcerative colitis.

Authors:  Lawrence Bai; Madeleine K D Scott; Ethan Steinberg; Laurynas Kalesinskas; Aida Habtezion; Nigam H Shah; Purvesh Khatri
Journal:  J Am Med Inform Assoc       Date:  2021-10-12       Impact factor: 4.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.